Long-term effect of sublingual and subcutaneous immunotherapy in dust mite–allergic children with asthma/rhinitis: A 3-year prospective randomized controlled trial

Journal of Investigational Allergology and Clinical Immunology

Volumn 25, Issue 5, 2015, Pages 334-342

  Karakoc Aydiner, Elif ^a   Eifan, A O ^a,b   Baris, S ^a   Gunay, E ^a   Akturk, E ^a   Akkoc, T ^a   Bahceciler, N N ^a,c   Barlan, I B ^a  

^a MARMARA UNIVERSITY   (Turkey)

^b NATIONAL HEART AND LUNG INSTITUTE   (United Kingdom)

^c NEAR EAST UNIVERSITY   (Turkey)

Author keywords

Asthma; Children; House dust mites; Immunotherapy; Subcutaneous immunotherapy; Sublingual immunotherapy

Indexed keywords

ALLERGEN; GAMMA INTERFERON; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G4; INTERLEUKIN 10; INTERLEUKIN 5; ANTIASTHMATIC AGENT; ARTHROPOD PROTEIN; CYSTEINE PROTEINASE; DERMATOPHAGOIDES PTERONYSSINUS ANTIGEN P 1; DERMATOPHAGOIDES PTERONYSSINUS ANTIGEN P 2; HOUSE DUST ALLERGEN; IL10 PROTEIN, HUMAN; IL5 PROTEIN, HUMAN; IMMUNOGLOBULIN G;

ARTICLE; ASTHMA; BRONCHUS HYPERREACTIVITY; CHILD; CONTROLLED STUDY; DERMATOPHAGOIDES FARINAE; DERMATOPHAGOIDES PTERONYSSINUS; FEMALE; HUMAN; LUNG FUNCTION TEST; MALE; NOSE PROVOCATION TEST; PERIPHERAL BLOOD MONONUCLEAR CELL; PROSPECTIVE STUDY; RANDOMIZED CONTROLLED TRIAL; RHINITIS; SCHOOL CHILD; SUBCUTANEOUS IMMUNOTHERAPY; SUBLINGUAL IMMUNOTHERAPY; ANIMAL; COMPARATIVE STUDY; COMPLICATION; DESENSITIZATION; FORCED EXPIRATORY VOLUME; HYPERSENSITIVITY; IMMUNOLOGY; LONGITUDINAL STUDY; MONONUCLEAR CELL; PROCEDURES; PYROGLYPHIDAE; RHINITIS, ALLERGIC; SUBCUTANEOUS DRUG ADMINISTRATION; TREATMENT OUTCOME;

ANIMALS; ANTI-ASTHMATIC AGENTS; ANTIGENS, DERMATOPHAGOIDES; ARTHROPOD PROTEINS; ASTHMA; CHILD; CYSTEINE ENDOPEPTIDASES; DESENSITIZATION, IMMUNOLOGIC; FEMALE; FORCED EXPIRATORY VOLUME; HUMANS; HYPERSENSITIVITY; IMMUNOGLOBULIN E; IMMUNOGLOBULIN G; INJECTIONS, SUBCUTANEOUS; INTERFERON-GAMMA; INTERLEUKIN-10; INTERLEUKIN-5; LEUKOCYTES, MONONUCLEAR; LONGITUDINAL STUDIES; MALE; PYROGLYPHIDAE; RHINITIS, ALLERGIC; SUBLINGUAL IMMUNOTHERAPY; TREATMENT OUTCOME;

EID: 84946044245     PISSN: 10189068     EISSN: 16980808     Source Type: Journal    
DOI: None     Document Type: Article

References (32)

1. Eder W, Ege MJ, von Mutius E. The asthma epidemic. N Engl J Med. 2006; 355:2226–35
2. Platts-Mills T, de Weck AL, Aalberse R, Bessot JC, Bjorksten B, Bischoff E, Bousquet J, Van Bronswijk J, ChannaBasavanna GP, Chapman M, Colloff M, et al. Dust mite allergens and asthma--a worldwide problem. J Allergy Clin Immunol. 1989 Feb;83(2 Pt 1):416-27
3. Sheikh A, Hurwitz B, Nurmatov U, van Schayck CP. House dust mite avoidance measures for perennial allergic rhinitis. Cochrane Database Syst Rev. 2010 Jul 7;(7):CD001563
4. Gøtzsche PC, Johansen HK. House dust mite control measures for asthma. Cochrane Database Syst Rev. 2008 Apr 16;(2):CD001187
5. Jacobsen L, Niggemann B, Dreborg S, Ferdousi HA, Halken S, Høst A, Koivikko A, Norberg LA, Valovirta E, Wahn U, Möller C; (The PAT investigator group). Specific immunotherapy has longterm preventive effect of seasonal and perennial asthma: 10-year follow-up on the PAT study. Allergy. 2007;62:943–948
6. Bacharier LB, Boner A, Carlsen KH, Eigenmann PA, Frischer T, Götz M, Helms PJ, Hunt J, Liu A, Papadopoulos N, Platts-Mills T, Pohunek P, Simons FE, Valovirta E, Wahn U, Wildhaber J; European Pediatric Asthma Group. Diagnosis and treatment of asthma in childhood: a PRACTALL consensus report. Allergy. 2008;63:5-34
7. EMEA. Guideline on the clinical development on products for specific immunotherapy for the treatment of allergic diseases. EMEA; 2008. Report No. CHMP/EWP/18504/2006.Available at: http://www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003605.pdf
8. Eifan AO, Shamji MH, Durham SR. Long-term clinical and immunological effects of allergen immunotherapy. Curr Opin Allergy Clin Immunol. 2011 Dec;11(6):586-93
9. Akdis CA, Akdis M. Mechanisms of allergen-specific immunotherapy. J Allergy Clin Immunol. 2011;127:18-27
10. Ozdemir C, Yazi D, Gocmen I, Yesil O, Aydogan M, Semic-Jusufagic A, Bahceciler NN, Barlan IB. Efficacy of long-termsublingual immunotherapy as an adjunct to pharmacotherapy in house dust mite-allergic children with asthma. Pediatr Allergy Immunol. 2007;18:508-515 59.
11. Stelmach I, Sobocińska A, Majak P, Smejda K, Jerzyńska J, Stelmach W. Comparison of the long-term efficacy of 3-and 5-year house dust mite allergen immunotherapy. Ann Allergy Asthma Immunol. 2012 Oct;109(4):274-8
12. Global initiative for asthma management and prevention: NHLBI/WHO Workshop report, National Heart, Lung and Blood Institute, Bethesda, MD, 2006 GINA guidelines
13. Eifan AO, Akkoc T, Yildiz A, Keles S, Ozdemir C, Bahceciler NN, Barlan IB. Clinical efficacy and immunological mechanisms of sublingual and subcutaneous immunotherapy in asthmatic/ rhinitis children sensitized to house dust mite: an open randomized controlled trial. Clin Exp Allergy. 2010;40:922-32
14. Crapo RO, Casaburi R, Coates AL, Enright PL, Hankinson JL, Irvin CG, MacIntyre NR, McKay RT, Wanger JS, Anderson SD, Cockcroft DW, Fish JE, Sterk PJ. Guidelines for methacholine and exercise challenge testing-1999. This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, July 1999. Am J Respir Crit Care Med. 2000 Jan;161(1):309-29
15. Abramson MJ, Puy RM, Weiner JM. Injection allergen immunotherapy for asthma. Cochrane Database Syst Rev. 2010;8:CD001186
16. Radulovic S, Calderon MA, Wilson D, Durham S. Sublingual immunotherapy for allergic rhinitis. Cochrane Database Syst Rev. 2010 Dec 8;(12):CD002893
17. Compalati E, Passalacqua G, Bonini M, Canonica GW. The efficacy of sublingual immunotherapy for house dust mites respiratory allergy: results of a GA2LEN meta-analysis. Allergy. 2009 Nov;64(11):1570-9
18. Olaguibel JM, Puebla MJA. Efficacy of sublingual allergen vaccination for respiratory allergy in children. Conclusions from one meta-analysis. Journal of Investigational Allergology and Clinical Immunology. 2005;15:9-16
19. Piazza I, Bizzaro N. Humoral response to subcutaneous, oral, and nasal immunotherapy for allergic rhinitis due to Dermatophagoides pteronyssinus. Ann Allergy. 1993 Nov;71(5):461-9
20. Mungan D, Misirligil Z, Gürbüz L. Comparison of the efficacy of subcutaneous and sublingual immunotherapy in mite-sensitive patients with rhinitis and asthma--a placebo controlled study. Ann Allergy Asthma Immunol. 1999 May;82(5):485-90
21. Keles S, Karakoc-Aydiner E, Ozen A, Izgi AG, Tevetoglu A, Akkoc T, Bahceciler NN, Barlan I. A novel approach in allergenspecific immunotherapy: combination of sublingual and subcutaneous routes. J Allergy Clin Immunol. 2011;128:808-15
22. Yukselen A, Kendirli SG, Yilmaz M, Altintas DU, Karakoc GB. Effect of one-year subcutaneous and sublingual immunotherapy on clinical and laboratory parameters in children with rhinitis and asthma: a randomized, placebocontrolled, double-blind, double-dummy study. Int Arch Allergy Immunol. 2012;157(3):288-98
23. Cools M, Van Bever HP, Weyler JJ, Stevens WJ. Long-term effects of specific immunotherapy, administered during childhood, in asthmatic patients allergic to either house-dust mite or to both house-dust mite and grass pollen. Allergy. 2000 Jan;55(1):69-73
24. Tabar AI, Arroabarren E, Echechipía S, García BE, Martin S, Alvarez-Puebla MJ. Three years of specific immunotherapy may be sufficient in house dust mite respiratory allergy. J Allergy Clin Immunol. 2011 Jan;127(1):57-63, 63.e1-3
25. Olaguibel JM, Tabar AI, Garcia BE, Martin S, Rico P. Longterm immunotherapy with an optimal maintenance dose of a standardized Dermatophagoides pteronyssinus extract in asthmatic patients. J Investig Allergol Clin Immunol. 1999;9:110-6
26. Marogna M, Spadolini I, Massolo A, Canonica GW, Passalacqua G. Long-lasting effects of sublingual immunotherapy according to its duration: a 15-year prospective study. J Allergy Clin Immunol. 2010 Nov;126(5):969-75
27. Di Rienzo V, Marcucci F, Puccinelli P, Parmiani S, Frati F, Sensi L, Canonica GW, Passalacqua G. Long-lasting effect of sublingual immunotherapy in children with asthma due to house dust mite: a 10-year prospective study. Clin Exp Allergy. 2003 Feb;33(2):206-10
28. Tahamiler R, Saritzali G, Canakcioglu S, Ozcora E, Dirican A. Comparison of the long-term efficacy of subcutaneous and sublingual immunotherapies in perennial rhinitis. ORL J Otorhinolaryngol Relat Spec. 2008;70(3):144-50
29. Durham SR, Emminger W, Kapp A, de Monchy JG, Rak S, Scadding GK, Wurtzen PA, Andersen JS, Tholstrup B, Riis B, Dahl R. SQ-standardized sublingual grass immunotherapy: Confirmation of disease modification 2 years after 3 years of treatment in a randomized trial. J Allergy Clin Immunol. 2012 Mar;129(3):717-725.e5
30. Pichler CE, Helbling A, Pichler WJ. Three years of specific immunotherapy with house-dust-mite extracts in patients with rhinitis and asthma: significant improvement of allergen-specific parameters and of nonspecific bronchial hyperreactivity. Allergy. 2001 Apr;56(4):301-6
31. Quirino T, Iemoli E, Siciliani E, Parmiani S, Milazzo F. Sublingual versus injective immunotherapy in grass pollen allergic patients: a double blind (double dummy) study. Clin Exp Allergy. 1996 Nov;26(11):1253-61
32. Shamji MH, Ljørring C, Francis JN, Calderon MA, Larché M, Kimber I, Frew AJ, Ipsen H, Lund K, Würtzen PA, Durham SR. Functional rather than immunoreactive levels of IgG4 correlate closely with clinical response to grass pollen immunotherapy. Allergy. 2012 Feb;67(2):217-26.